protein

Surfactant Protein B Blocking Peptide

MBS824192

1 mg

160 USD

Blocking Peptide

Surfactant Protein B Blocking Peptide

[Surfactant Protein B]

[SFTP3; Pulmonary surfactant-associated protein B; SP-B; 18 kDa pulmonary-surfactant protein; 6 kDa protein; Pulmonary surfactant-associated proteolipid SPL(Phe)]

[pulmonary surfactant-associated protein B; Pulmonary surfactant-associated protein B; pulmonary surfactant-associated protein B; 6 kDa protein; 18 kDa pulmonary-surfactant protein; pulmonary surfactant-associated proteolipid SPL(Phe); surfactant protein B; 18 kDa pulmonary-surfactant protein; 6 kDa protein; Pulmonary surfactant-associated proteolipid SPL(Phe)]

[SFTPB]

[SFTPB; SFTPB; SP-B; PSP-B; SFTB3; SFTP3; SMDP1; SFTP3; SP-B]

PSPB_HUMAN

Synthetic

Human

393

>85%

Lyophilized powder

Shipped at 4°C. Store at -20°C for one year.

Blocking (BL)

Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4 degree C for overnight or at room temperature for 2 hours.

Quality Control: The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry.

The peptide is used to block Anti-Surfactant Protein B Antibody (catalog #MBS820599) reactivity.

288856299

NP_000533.3

NM_000542.3

P019075

42,117 Da

This gene encodes the pulmonary-associated surfactant protein B (SPB), an amphipathic surfactant protein essential for lung function and homeostasis after birth. Pulmonary surfactant is a surface-active lipoprotein complex composed of 90% lipids and 10% proteins which include plasma proteins and apolipoproteins SPA, SPB, SPC and SPD. The surfactant is secreted by the alveolar cells of the lung and maintains the stability of pulmonary tissue by reducing the surface tension of fluids that coat the lung. The SPB enhances the rate of spreading and increases the stability of surfactant monolayers in vitro. Multiple mutations in this gene have been identified, which cause pulmonary surfactant metabolism dysfunction type 1, also called pulmonary alveolar proteinosis due to surfactant protein B deficiency, and are associated with fatal respiratory distress in the neonatal period. Alternatively spliced transcript variants encoding the same protein have been identified.[provided by RefSeq, Feb 2010]

SFTPB: Pulmonary surfactant-associated proteins promote alveolar stability by lowering the surface tension at the air- liquid interface in the peripheral air spaces. SP-B increases the collapse pressure of palmitic acid to nearly 70 millinewtons per meter. Defects in SFTPB are the cause of pulmonary surfactant metabolism dysfunction type 1 (SMDP1); also called pulmonary alveolar proteinosis due to surfactant protein B deficiency. A rare lung disorder due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid- Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress. Genetic variations in SFTPB are a cause of susceptibility to respiratory distress syndrome in premature infants (RDS). RDS is a lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high-permeability lung edema and fibrin-rich alveolar deposits called hyaline membranes . A variation Ile to Thr at position 131 influences the association between specific alleles of SFTPA1 and respiratory distress syndrome in premature infants. Protein type: Secreted, signal peptide; Secreted. Chromosomal Location of Human Ortholog: 2p12-p11.2. Cellular Component: extracellular space; lysosome. Biological Process: organ morphogenesis; sphingolipid metabolic process; respiratory gaseous exchange. Disease: Surfactant Metabolism Dysfunction, Pulmonary, 1

1 mg

160 USD

5 mg

305